Registered / treated patients (n=70)

Evaluable patients for safety (n=70)
Eligible patients (n=66)

Protocol violation
No histologically or cytologically confirmed diagnosis of NSCLC cancer stage IIIA-IIIB (n=2)
Stade VI confirmed after inclusion (n=2)

Reason for treatment discontinuation
Adverse event (Grade 3 fatigue) (n=1)

Completed induction CT (n=69)

Reason for treatment discontinuation (n=20)
Progressive Disease (n=5)
Adverse event/excessive toxicity (n=5)
Metastases at study entry, patient withdrawn from the study (n=2)
Death for progression (n=1)
Death for neither progression nor toxicity (n=1)
Protocol violation leading to withdrawal from the study (n=2)
Surgery at the end of induction (n=4)

 Entered CT-RT (n=49)

Reason for treatment discontinuation (n=2)
Protocol violation (RT stopped at 50, 4 Gy) (n=1)
Disease progression (n=1)

Completed CT-RT (n=47)